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Background: Semantic Web technology can considerably catalyze translational genetics and genomics research
in medicine, where the interchange of information between basic research and clinical levels becomes crucial.
This exchange involves mapping abstract phenotype descriptions from research resources, such as knowledge
databases and catalogs, to unstructured datasets produced through experimental methods and clinical practice.
This is especially true for the construction of mutation databases. This paper presents a way of harmonizing abstract
phenotype descriptions with patient data from clinical practice, and querying this dataset about relationships
between phenotypes and genetic variants, at different levels of abstraction.
Methods: Due to the current availability of ontological and terminological resources that have already reached
some consensus in biomedicine, a reuse-based ontology engineering approach was followed. The proposed
approach uses the Ontology Web Language (OWL) to represent the phenotype ontology and the patient model,
the Semantic Web Rule Language (SWRL) to bridge the gap between phenotype descriptions and clinical data, and
the Semantic Query Web Rule Language (SQWRL) to query relevant phenotype-genotype bidirectional relationships.
The work tests the use of semantic web technology in the biomedical research domain named cerebrotendinous
xanthomatosis (CTX), using a real dataset and ontologies.
Results: A framework to query relevant phenotype-genotype bidirectional relationships is provided. Phenotype
descriptions and patient data were harmonized by defining 28 Horn-like rules in terms of the OWL concepts.
In total, 24 patterns of SWQRL queries were designed following the initial list of competency questions. As the
approach is based on OWL, the semantic of the framework adapts the standard logical model of an open world
assumption.
Conclusions: This work demonstrates how semantic web technologies can be used to support flexible
representation and computational inference mechanisms required to query patient datasets at different levels of
abstraction. The open world assumption is especially good for describing only partially known phenotype-genotype
relationships, in a way that is easily extensible. In future, this type of approach could offer researchers a valuable
resource to infer new data from patient data for statistical analysis in translational research. In conclusion,
phenotype description formalization and mapping to clinical data are two key elements for interchanging
knowledge between basic and clinical research.* Correspondence: maria.taboada@usc.es
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Cerebrotendinous xanthomatosis (CTX) is a rare lipid-
storage disease that leads to a complex combination of
neurologic dysfunctions including cerebellar, pyramidal
and extrapyramidal signs, neuropathy, dementia and
psychiatric disturbances, as well as extra-neurological
manifestations (chronic diarrhea, cataracts, tendon xan-
thomas, premature arteriosclerosis) [1]. CTX is caused
by mutations in the gene CYP27A1, which encodes the
mitochondrial enzyme sterol 27-hydroxylase, deficiency
of which causes an excess of intermediate metabolites
such as cholestanol to accumulate in virtually every
tissue. Like many neurodegenerative disorders, CTX is
characterized by an insidious onset, progressive course
and variable combination of clinical manifestations in
each patient, which, together with the rarity of the dis-
ease, hampers correct and early diagnosis. Therapeutic
delay is especially catastrophic in CTX, since there is a
specific treatment (chenodeoxycolic acid), which is
effective in reducing the plasma levels of cholestanol
but has not been demonstrated to improve established
neurological deficits. Mutation analysis of the CYP27A1
gene is a key step in the diagnosis of CTX and is
routinely performed. The availability of comprehen-
sive genotype to phenotype data sets will be crucial in
order to promote early recognition and optimize the
diagnostic process.
In any disease but most especially in rare diseases
the possibility of accessing detailed patient datasets from
research and clinical studies, including genetic variants
and phenotypic manifestations, would significantly
improve diagnosis and treatment. Electronic patient
records are able to gather diverse types and growing
amounts of phenotypic data, while the use of genome-
scale DNA sequencing techniques allows the collection
of an increasing number of genetic variants per individ-
ual. Thus, integrating complex phenotype descriptions
with genetic testing records has become one of the main
challenges of biomedicine [2]. As the number of openly
accessible datasets continues to rise, the integration of
research repositories and patient clinical data will be
more viable. However, bioinformatics tools are needed
to help explore complex genotype-phenotype relation-
ships. Geneticists would request software tools able to
retrieve and analyze the data produced in diverse clinical
settings and associated to a new given genetic variant;
that is, answering questions like what are the phenotype
traits that have been identified in patients with this gen-
etic variation? Clinicians, on the other hand, would see
their work greatly facilitated by being able to answer
queries like what genes or genetic variants are associated
with this particular combination of observable features?
The development of locus-specific mutation databases
(LSDBs) and tools to build them such as the LeidenOpen Variation Database (LOVD) [3], and the Universal
Mutation Database (UMD) [4] started to pave the way
to solve the problem of collecting genetic datasets pro-
duced by diverse experimental methods in different
laboratories. However, the phenotype description in
most LSDBs is very scarce. The Human Variome Project
(HVP) [5] is an international initiative aiming ultimately
at the worldwide collection and harmonization of all
human genetic variations and associated phenotypic
data. The GEN2PHEN project also represents an inter-
national attempt to undertake the logistical and tech-
nical challenges to join disparate genotype-phenotype
resources in a shared mode [6]. In order to achieve that
goal, communication standards are needed to allow
interoperability between clinical and genetic datasets.
Standards to represent genetic findings are already
available, such as those produced by the HUGO
committee (http://www.genenames.org/aboutHGNC.html),
gene relationships provided by Gene Ontology [7] or the
nomenclature for description of sequence variants pro-
posed by the Human Genome Variation Society (HGVS,
www.hgvs.org/mutnomen). However, such a level of con-
sensus on the best descriptors for phenotypic informa-
tion is far more complex and has not been reached in
clinical medicine.
Although the term phenotype covers an extensive
range of information varying from molecular to organ-
ism level observable characteristics [8], in this work
phenotype is meant only as any observable human trait,
such as an anatomical abnormality (e.g., juvenile catar-
acts) or a clinical feature (e.g., tendon xanthomas). Cur-
rently, the most useful catalog of human Mendelian
disorders is OMIM, the Online Mendelian Inheritance
in Man [9], a text-based knowledge source of human
phenotypes and related genes. OMIM describes pheno-
types using narrative sentences (e.g. normal to slightly
elevated plasma cholesterol). Although these textual
descriptions are highly expressive, capturing phenotype
information using free-text fields in databases hampers
computational processing and inference [10]. The use of
a standard terminology provides a more appropriate
method of expressing unambiguous, computable, and
interoperable phenotype descriptions. Standard termin-
ologies organize the concepts of a particular domain into
a taxonomy (e.g., epilepsy is a seizure disorder, which is
an abnormality of the central nervous system), assigning
them identifiers which do not change with new versions.
They also address the issues of different synonyms for
the same concept (e.g., convulsions vs. epileptic seizures).
Patient data from clinical and research settings are
usually stored in different formats, from simple spread-
sheets to relational databases, being extremely difficult
to integrate genotype-phenotype data across multiple
formats. The semantic web technology provides an
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dardized fashion and with a high degree of expressivity.
Using this technology to represent data will ensure the
compatibility of them with the future knowledge and
data resources. Additionally, one of the main challenges
of articulating queries on phenotype-genotype relation-
ships is discrepancy in the level of abstraction between
phenotype descriptions and patient clinical data. The
semantic web technology provides a layer of abstraction
that makes it simple to use. Moreover, this technology is
based on open world assumption: everything we do not
know is undefined. Hence, unknown relationships will
be interpreted as not computable instead of false. This
approach naturally deals with incomplete information,
which is very usual in biomedicine, and it is able to
refine knowledge when new information comes along.
One option to deal with the phenotype complexity
can be to define a minimum set of phenotype template
fields [11]. In contrast, an ontology-based technology
would provide a more open and flexible representation
mechanism [10,12-14], thus facilitating the continuing
incorporation and interpretation of new phenotype char-
acteristics. An ontology is a data model that represents a
set of entities in some domain and the relationships
among those entities. One of the benefits of using ontol-
ogies is the potential to apply reasoners (logical infer-
ence tools), which can infer new data to subsequently
facilitate query answering and statistical analysis. In the
present work, we used patient data from a specific
rare genetic disease (CTX) to formally represent pheno-
type descriptions using the ontological paradigm [15].
We then engineered the patient data in an ontology-
based patient model and finally executed queries on
genotype-phenotype relationships with a Semantic
Web approach.
Methods
Overview of the query process
Since the main goal of our work was to develop an
approach to query genotype-phenotype relationships on
patient datasets, we set out a list of competency ques-
tions [16], i.e., questions that our approach should be
able to answer. Then, we analyzed the query process in
order to determine the steps required to optimize the
answers. The list of competency questions included
queries such as the one showed in Figure 1. These quer-
ies are expressed with phenotype descriptions like those
used in genetic catalogs (e.g., childhood-onset chronic
diarrhea). Patient clinical data, however, usually contain
this information in a lower level of abstraction, often
distributed in several fields (e.g., diarrhea onset age and
diarrhea duration). Thus, a tool provided with a query
like the one in Figure 1 should carry out, at least, two
steps: first, successfully interpreting the meaning ofchildhood-onset chronic diarrhea and second, adequately
mapping the query to the dataset.
Additionally, queries such as ‘What genetic variants
have been identified in patients without childhood-onset
chronic diarrhea?’ will return those genetic variants for
patients with asserted absence of childhood-onset chronic
diarrhea, that is, the genetic variant p.R395C (patient
564385–1) in Figure 1. But, it will not include those
patients for which there is unknown or missing informa-
tion (open-world assumption); that is, it will say “Do
not know” for the genetic variants c.844 + 1 G->T y p.
Q525X, unless a blank is interpreted as ‘not (childhood-
onset chronic diarrhea)’.
Finally, if phenotype descriptions are organized in an
is_a hierarchy, queries for broader phenotypes should
return genetic variants associated with these phenotypes
as well as with narrower phenotypes. For example, the
query Select genetic variants associated with Abnormal-
ity of the Cerebellum should also return genetic variants
associated with Ataxia and Arnold-Chiari type I malfor-
mation (Figure 2).
Data and knowledge sources
Patient Datasets: The complete and detailed patient
dataset published on a PhD dissertation written in Span-
ish [17] was used in our approach. Currently, these data
are also available in English in a more summarized form
[18]. These patient data originated from a thorough col-
laborative clinical and genetic study on CTX carried out
at the Hospital Ramón y Cajal (Madrid) and the Funda-
ción Pública Galega de Medicina Xenómica (Santiago
de Compostela) in Spain.
In brief, 25 patients from 19 families were thoroughly
studied through personal examination of the patients
and their medical records by the authors (BP, AJE, MJS).
Detailed clinical history data, neurological signs, neuro-
physiologic, biochemical and neuroimaging data were
collected in extensive table and text format.
Text-based resources: Two text-based resources from
highly reliable web sites were searched in our approach,
the OMIM clinical synopsis (http://www.ncbi.nlm.nih.
gov/omim/213700?dopt=Synopsis; [19]) and the Sum-
mary, Diagnosis and Clinical Description sections of
GeneReviews (http://www.ncbi.nlm.nih.gov/bookshelf/
br.fcgi?book=gene&part=ctx), both of them containing
known phenotype manifestations of CTX.
Terminology systems: The Unified Medical Language
System (UMLS¸ http://umlsks.nlm.nih.gov) Metathe-
saurus was chosen to codify the relevant CTX termin-
ology extracted from the text-based resources.
Domain ontologies: Two web sites actively used in
biomedical communities, the NCBO Bioportal (http://
bioportal.bioontology.org; [20]) and the OBO Foundry
(http://www.obofoundry.org; [21]), were accessed to
Figure 1 Steps required to answering questions on phenotype-genotype relationships. The figure includes an example showing the
genetic variants that have been identified in patients with childhood-onset chronic diarrhea (i.e., p.Q230X, p.R395C, p.R405W and p.T343R).
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domain of CTX.
Ontology development
Our approach distinguishes three levels (Figure 3): the
Knowledge Resource Layer, in which several resources in
different formats can be found; the Semantic Web Layer,
which provides the domain terminologies, ontologies
and data, as well as, inference and deductive capabilities
to increase the usability and reusability of data; and
the Semantic Query Layer, which supplies tools and
languages for semantic query processing.
CTX phenotype-genotype relationships are repre-
sented in the Semantic Web Layer via a patient data
model expressed in terms of a CTX phenotype ontology.
We developed this ontology following the reuse-based
methodology NeOn [16], thanks to the current availabil-
ity of ontological and terminological resources that have
reached some consensus in biomedicine. Although
NeOn is focused on collaboratively building ontology
networks, it is currently the only one covering complexscenarios with reuse of ontological and non-ontological
resources. Initially, a set of use cases describing phenotype-
genotype bidirectional relationships and query support
were specified in order to determine the content of our
ontology. Thus, the ontology should represent CTX phe-
notypes, genetic variants, and bidirectional relationships
between them. Next, we developed the CTX ontology
carrying out several activities proposed by the NeOn
methodology: extracting the CTX terminology, assessing
the publicly available resources, reusing and reengineer-
ing the selected resources. The ontology was developed
using the Web Ontology Language (OWL) [22] and
Protégé-OWL 3.4 [23].
Extracting the CTX terminology
One of the critical steps when developing ontologies is
to identify the particular knowledge to be represented
in the ontology. Usually, this activity is carried out at
the beginning of the ontology project through a set of
interviews with domain experts. Since this activity is
labor-intensive, we decided to semi-automatically extract
Figure 2 Example of hierarchical (‘is-a’) relationships between Abnormalities of the Central Nervous System and more specific
disorders, such as Epilepsy or Ataxia.
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employed in this work. Then, we manually checked the
extracted terminology, and we eliminated erroneously
extracted concepts, very general concepts (e.g., Findings)
and some terms that did not represent concepts relevant
to CTX.Figure 3 Layers of the approach proposed in this work.Assessing terminological and ontological resources
We searched the term Cerebrotendinous Xanthomatosis
in the NCBO Bioportal and in the OBO Foundry
resources. Next, we assessed the candidate ontologies
from these resources by calculating their coverage with
respect to the glossary of CTX terms.
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We built the CTX ontology by reusing concepts and
relationships from the selected resources in the last step.
Construction of patient data model in OWL
We developed an OWL model describing the patient
dataset and the relationships between phenotypic and
genotypic data, where the former are expressed in terms
of the CTX phenotype ontology.
Querying phenotype-genotype bidirectional relationships
In order to have the ability to execute queries at differ-
ent levels of abstraction, firstly a set of rules was defined
to successfully interpret the meaning of phenotype
descriptions (step 1 in Figure 1). This set of rules was
implemented by means of the Semantic Web Rule Lan-
guage (SWRL) [24], a language to express Horn-like
rules in terms of OWL concepts. Next, in order to formu-
late queries traversing bidirectional phenotype-genotype
relationships on patient data (step 2 in Figure 1), we used
SQWRL [25], a language that expands SWRL in order to
provide querying of OWL ontologies.
Results
The CTX ontology
Extracting the CTX terminology
Table 1 summarizes the quantitative results obtained
from extracting the glossary of CTX terms using differ-
ent terminological services provided by the UMLSKS
Knowledge Server (ExactMatch, NormalizedString and
Metamap; [26]). After manually revising the extracted
terminology, the glossary of relevant terms for CTX
comprised a total of 93 UMLS concepts.
Assessing terminological and ontological resources
Upon searching the term Cerebrotendinous Xanthomato-
sis in the NCBO Bioportal, 15 ontologies were displayed,
some of them being collateral to the domain, such as
DermLex, a terminology of the dermatologic domain, or
RadLex, a lexicon in the radiology domain. We selected
Snomed CT, as it is a large clinical terminology system
containing formal definitions for clinical concepts using
hierarchical and non-hierarchical relationships. We then
examined the OBO Foundry resources and here twoTable 1 Percentage of match of CTX terminology extracted fr
Strings/Sentences #
Patient Data (ExactMatch) 65
Patient Data (ExactMatch +MetaMap) 65
OMIM (NormalizeString) 23
GeneReviews (MetaMap) 83
The F measure represents 2 (P R)/(P + R), the geometric mean of the precision (P) an
retrieval from documents.ontologies related to the phenotype domain were
selected as candidates: the Human Phenotype Ontology
(HPO) [27], covering human phenotypic abnormalities,
and the Phenotypic Quality (PATO) [10], involving
phenotypic qualities necessary to reach a complete
description of phenotypes. Table 2 shows the coverage
of relevant CTX terminology in the candidate ontolo-
gies, itemized by Disorders and Abnormalities, Anatom-
ical Structures, Diagnostic Studies and Qualifier Values.Reusing terminological and ontological resources
Although the coverage of relevant CTX terminology in
Snomed CT was slightly higher than in HPO (Table 2),
we decided to reuse HPO and extend it with the
required Snomed CT concepts and relationships. The
justification is the following: the organization of HPO
follows the structure of OMIM, which is very close to
experts in CTX, HPO is less complex than Snomed CT
and it can be easily translated to OWL.
All concepts were integrated within the target applica-
tion as phenotype management ontology, consisting of
four main hierarchies: Phenotype, Anatomical Structure,
Diagnostic Studies and Qualifier Values. Table 3 shows
the total number of concepts in the OWL ontology
(279), detailing the number of terms pulled from HPO
and SNOMED CT, as well as the number of new con-
cepts (those not included in either HPO or Snomed
CT). Reusing classes and hierarchies greatly reduces the
effort needed by medically qualified personnel, which
only participated in curation tasks (deciding the most
suitable hierarchy in case of multiple options, position-
ing a new concept and revising the complete ontology).
In addition, it was necessary to distinguish among the
presence and the absence of a phenotypic trait in a given
patient. Therefore, we subdivided each phenotype into
two OWL instances covering the two possibilities. For
example, for the phenotype Epilepsy, there are two pos-
sible instances: presence of epilepsy and absence of epi-
lepsy. Hence, there are three types of patients: those
ones with asserted presence of epilepsy, those ones with
asserted absence of epilepsy, and finally those ones
for which there is no information about the presence or
absence of epilepsy.om different sources
Precision Recall F-Measure
93 % 67 % 78 %
94 % 94 % 94 %
100 % 100 % 100 %
88 % 79 % 83 %
d recall (R), which is a standard measure for the goodness of information









Snomed CT 56 6 11 11
(93.3 %) (100 %) (92 %) (73.3 %)
HPO 50 —— —— ———
(83.3 %)
PATO —— —— —— 5
(33.3 %)
Total 60 6 12 15
(100 %) (100 %) (100 %) (100 %)
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We created object properties to represent patient mani-
festations: gene mutations, extra-neurological symptoms,
neurological symptoms, results from diagnostic studies
and other manifestations. Then, the patient model
was populated manually. In total, 1 class, 17 properties
and 25 individuals represent the Patient Model in
our ontology.
Querying phenotype-genotype bidirectional relationships
Before formulating queries traversing phenotype-
genotype relationships, we defined a set of 28 rules to
deduce abstract phenotype descriptions from the patient
data. Supplementary data provides all rules defined in
our system. The execution of the rules generates the
corresponding links (e.g., has extra-neurological manifes-
tations’) between the corresponding patient instances
and the abstract phenotype instances. Next, we formu-
late some of the queries defined in the initial list of com-
petency questions, showing how the approach can help
us to analyze the CTX dataset. (Supplementary data pro-
vides the complete list of queries, showing the corre-
sponding SQWRL implementation and the answers in
every case).
Example 1: In the CTX study, the presence of child-
hood-onset chronic diarrhea was confirmed in 44 % of
patients. The reply to the query ‘What genetic variants
are associated with childhood-onset chronic diarrhea?’
substantiates that only 7 from 14 genetic variants (50 %)







(55 %)answer to ‘What are the genetic variants that have
always been associated with childhood-onset chronic
diarrhea?’ verifies that only one genetic variant (p.
R395C) is associated with both the presence and absence
of the manifestation, whereas the remaining 6 genetic
variants are always associated with the presence of this
manifestation. Our approach also provides queries like
‘What are the genetic variants that have never been
associated with childhood-onset chronic diarrhea?. In
the CTX study, only the generic variant p.Q525X was
never associated.
Example 2: In the CTX study, the presence of epilepsy
was corroborated in 32 % of patients, and the presence
of dementia in 52 % of patients. The answer to ‘What
genetic variants are associated with epilepsy and demen-
tia at the same time?’ confirms that only 6 from 14 gen-
etic variants (42 %) are associated (see Table 4).
Example 3: The study compiled the set of main neuro-
logical manifestations and their frequency. The request
‘What are the central nervous system manifestations that
have been identified in patients with p.R395C?’ supplies
us with the specific manifestations (Ataxia and Chiari
Type I) for a particular genetic variant (see Table 4).
Example 4: The CTX study linked the onset age of
neurological symptoms with the presence of xanthomas.
In patients with xanthomas, the average onset age of
neurological symptoms was 23 years in contrast with
16 years for patients without xanthomas. Inquiring
about What is the average onset age of nervous system
symptoms in patients with xanthomas and p.R405W?oncepts






(43 %) (2 %)
Table 4 Four examples of queries to the patient data
Pattern of CQ Examples of CQ Example of SQWRL Example of answers
What are the genetic variants
that have been associated with
a combination of traits?
What are the genetic variants
that have been associated
with epilepsy and dementia?
Patient(?p) ^ hasNervousSystemDisorder(?p, ?x)
^ Epilepsy(?x) ^ hasPresence(?x, ?y) ^ Yes(?y)
^ hasNervousSystemDisorder(?p, ?d)
^ Dementia(?d) ^ hasPresence(?d, ?y)
^ hasGeneMutation(?p, ?g) ^ GeneticMutation(?g)
^mutation(?g, ?m)! sqwrl:columnNames
("GeneMutation") ^ sqwrl:selectDistinct(?m)






What are the abnormalities that
have been associated with a
specific genetic variant?
What are the Abnormalities of
the Central Nervous System
that have been associated with
p.R395C?
Patient(?p1) ^ hasNervousSystemDisorder(?p1, ?z)
^ hasPresence(?z, ?y) ^ Yes(?y) ^
AbnormalityoftheCerebellum(?z) ^
hasGeneMutation(?p1, ?g) ˚ sqwrl:makeSet
(?s1, ?z) ^ Patient(?p2) ^ hasOtherManifestations
(?p2, ?x) ^ hasPresence(?x, ?y) ^
AbnormalityoftheCerebellum(?x) ^
hasGeneMutation(?p2, ?g) ^ sqwrl:makeSet
(?s2, ?x) ^ GeneMutation(?g) ^ mutation(?g, ?m)
^ swrlb:equal(?m, "p.R395C") ˚ sqwrl:append




How often has a specific genetic
variant been associated with a
specific trait?
How often has p.R395C been
associated with Ataxia?
Patient(?p1) ^ hasNervousSystemDisorder
(?p1, ?x) ^ Ataxia(?x) ^ hasPresence(?x, ?y)
^ Yes(?y) ^ hasGeneMutation(?p1, ?g) ^
GeneMutation(?g) ^ mutation(?g, ?m)
^ swrlb:equal(?m, "p.R395C") ˚ sqwrl:makeSet
(?s1, ?p1) ˚ sqwrl:size(?size1, ?s1) ^ Patient(?p2)
^ hasGeneMutation(?p2, ?g) ^ sqwrl:makeSet
(?s2, ?p2) ^ sqwrl:size(?size2, ?s2) ^ swrlb:multiply
(?mu, ?size1, 100.0) ^ swrlb:divide(?d, ?mu,
?size2)! sqwrl:select(?d)
57 %
What is the average number of
years from the onset of a symptom
to the onset of another symptom
(or diagnosis/death) in patients
with a given genetic variant?
What is the average number of
years from the onset of diarrhea
to the first neurological symptom
in patients with the genetic variant
p.R395C?
Patient(?p1) ^ hasGeneMutation(?p1, ?g)
^ GeneticMutation(?g) ^ mutation
(?g, "p.R395C") ^ hasDiarrheaAge(?p1, ?d)
^ AgeatFirstSymptom(?d) ^ age(?d, ?da) ^
hasNeurologicalSymptomsOnsetAge(?p, ?a)
^ AgeatFirstSymptom(?a) ^ age(?a, ?ca) ^
swrlb:subtract(?di, ?ca, ?da)! sqwrl:columnNames
("Average age from diarrhea to neurological
symptoms onset") ^ sqwrl:avg(?di)
7 years
The first query is about genetic variants associated with a specific combination of observable features; the second query is about phenotype traits associated to a
specific genetic variant; and the third and fourth ones are examples of querying information about frequency and elapsed time associated with the presence of a
specific genetic variant and trait.
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8 years before) when the same query is made for the
genetic variant p.R395C. Similarly, the query What is the
average onset age of nervous system symptoms in patients
without xanthomas and with p.R395C? confirms
12,7 years (more than 3 years before the general average
of patients). The system provides a specific query to ask
this type of questions directly: How long after the onset
of xanthomas the first neurological symptom appears in
patients with the genetic variant p.R395C compared to
all patients?
Table 4 shows two other examples of queries to the
patient data. Supplementary data provide the complete
set of 24 patterns of SWQRL queries, which were
designed following the competency questions. The results
obtained for all queries in the ontology were tested with
manual analysis during implementation. If a query didnot return the expected result (from manual analysis), we
assumed that the query was formulated wrongly and so, it
was changed until to get the manual result.
Discussion
Our approach shows how the ontological paradigm and
the semantic web languages OWL, SWRL and SQWRL
can be used in combination to develop tools to explore
phenotype-genotype bidirectional associations in the
particular clinical domain of CTX, a rare, autosomal-
recessive neurometabolic disease. Two quite similar
approaches were previously demonstrated in familial
hypercholesterolemia [28] and autism cases [29]. In the
first one, an ontology was used to guide the expert with
the choice of meaningful subsets of a large mass of gen-
omic and post-genomic data. In the second one, a spe-
cific domain ontology was developed and complemented
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function, to infer high-level phenotypic abstractions. An
interesting alternative to define some of these rules is
the use of OWL 2, a new version of OWL, which con-
siderably improves the OWL data types. Using OWL2,
concepts such as Childhood-onset chronic diarrhea will
be directly expressible with OWL2 using data type
restrictions to define ranges for the concepts. Another
option to define some SQWRL queries is to create
defined OWL classes (through asserting necessary and
sufficient conditions) and to use the reasoner to auto-
matically compute the inferred types.
Although the present work is limited to a very specific
domain and with data collected from only a limited
number of patients through a Spanish research study, it
shows the potential use in other rare diseases and larger
datasets. One of the main problems for the correct diag-
nosis and handling of rare genetic disorders is the diffi-
culty in recognizing their variable clinical expression, as
well as the early symptoms of the disease. We propose
here an example of the type of tools that can aid clinical
practice by querying about potential genetic causes of a
specific symptom combination. The power of this type
of tools will greatly depend on both the amount and
quality of data that nurture the system. Thus, two sets
of advancements are extremely necessary in order to
improve diagnosis and treatment of genetic diseases,
especially for rare diseases: 1) Promoting international
initiatives to gather large sets of accessible patient data
and 2) Developing phenotype ontologies and bioinfor-
matics tools, in order to query phenotype-genotype rela-
tionships. Achieving this necessary level of detailed
genotype and phenotype description while handling
patient datasets appropriately to protect individual confi-
dentiality, is a question that is being addressed by the
Human Variome Project consortium ethics committee [30].
The approach proposed here is a pilot model that
must be taken with due caution, especially with small
datasets. Variable penetrance and expressivity are com-
mon in neurogenetic disorders and phenotype trait de-
scription of a given patient will evolve with time. Thus,
phenotype-genotype correlations are certainly not abso-
lute. That is, we cannot assert that a patient with a
specific mutation will necessarily have the same pheno-
type as another patient stored in the database with
the same mutation. Still, if used with awareness of its
limitations, this type of genotype-phenotype exploration
will be of clinical utility. Furthermore, if the database
is big enough it might be interesting to derive risk
figures, although this is not at all easy to do directly in
OWL/SQWRL.
Although the procedure used to populate the CTX
ontology in this work was manual, this is not the most
suitable method to incorporate new patients to thepatient model. Managing this step is important for fur-
ther use of the ontology or work inspired in this
approach. Incorporating an ontology-based workflow to
annotate patient data resources automatically, as pro-
posed by [31], will provide the way of combining the
new resources with the existing CTX ontology. Add-
itionally, temporal dimensions to phenotypic data are
important for this clinical domain and competency ques-
tions. Modeling of timelines and temporal occurrence of
events is one of the most challenging problems in ontol-
ogy development. The patient data used in this study
only included temporal events referred to the patient
age when a given manifestation had taken place (e.g., age
onset of cataract) or temporal intervals referred to the
duration of some manifestations. Even with this limited
information, some relevant queries on temporal aspects
of phenotype-genotype relationships could be designed.
For example, ‘On average, how long was it from the
onset of chronic diarrhea to the first neurological symp-
tom in patients with CTX?’, ‘and in patients with CTX and
the mutation p.395 C?’ Another aspect to be improved in
the future is to explore the possibility of designing more
complex SWRL rules dealing with probabilistic classifica-
tion in order to deduce abstract phenotypes.
Our approach could also have limitations if the num-
ber of patient data increases extremely. Scalability issues
or the slowness of OWL stores and reasoners are some
of the disadvantages of using such a young technology
[13]. Even so, there are some ways of speeding up
searches in OWL. One interesting way is the use of the
OWL 2 EL (i.e. existential logic) subsets [32] to enable
more efficient reasoning and complex queries to support
scientific analyses. Although OWL EL is focused on
large-scale ontologies, exploring the OWL EL expressiv-
ity power, which is more limited than OWL, for repre-
senting and processing our approach, could be an
interesting area for future research. Another current
limitation to the use of this technology is the scarcity of
publicly available data sources. Although we cannot an-
ticipate the format of data sources in the future, even in
the case they were available in traditional databases and
not in OWL, this technology could be used by imple-
menting a bridge between the relational patient data-
bases and the phenotype ontology.
Currently two communities are making a big effort to
supply a full and comprehensive representation of the
clinical domain: The International Health Terminology
Standards Development Organization (IHTSDO), with
the Snomed CT common vocabulary, and the Open Bio-
medical Ontologies (OBO) Foundry initiative [21], pro-
viding an ontology repository covering different domains
of biomedicine. A recent study analyzing both commu-
nities concluded that it is premature to know whether
one or the other will supply the solution to the breadth
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these two strategies to represent the particular CTX
domain we selected the ontology HPO from the OBO
Foundry initiative, and extended it with Snomed CT
from IHTSDO and a limited number of newly created
terms. It should be emphasized that the goal of this work
was not to build an exhaustive and definitive ontology
for CTX, but to develop semantic web tools to query
phenotype-genotype relationships. An extra benefit of
this approach is that the ontology can then be reused for
other applications, such as differential diagnosis [34].
Conclusions
Our study shows that the Semantic Web paradigm pro-
vides the technology required to represent phenotype-
genotype relationships in diseases with complex and
variable manifestations such as CTX. We developed a
tool to query this type of relationships on patient data in
both directions and at different levels of abstraction.
While ontologies have been generally used in medicine
to describe unambiguous and standard terminologies
agreed by consensus, our approach makes use of the
ontological paradigm and semantic web technologies
to provide a structured framework to query about indi-
viduals presenting a combination of phenotype traits
or carrying specific genetic variants. The proposed
approach implies querying the patient data by designing
a patient data model in OWL and accessing them via
the phenotype ontology. A semantic web rule language
allowed us to infer phenotypic abstractions from patient
data and provided the required bridge between pheno-
typic abstractions and clinical data. Through the use of
this language, queries about phenotype-genotype rela-
tionships can now be formulated on the abstraction level
that is common in genetic databases. We believe that
our strategy is a promising approach for translational
medical research, which will help improve diagnosis and
thus early and effective treatment of genetic disorders.
This is especially true for rare diseases, where the num-
ber of affected individuals is small and therefore easy
data access and query is essential to the health care
community. Coordinated international initiatives such as
the HVP are crucial to promote the development of the
necessary tools as well as to provide openly accessible
patient data.
Availability and requirements
The CTX ontology in OWL and all information relevant
to the paper is provided in following link: http://www.usc.
es/keam/CTX/TheCTXOntology.html, which contains
 The complete list of Competency Questions (QC).
 Several diagrams showing the main hierarchies of
the CTX phenotype management ontology. The complete list of SWRL rules implemented in
our approach.
 The complete list of patterns of queries
implemented in our approach. These groups of
queries were designed following the list of CQ.
 The patient model and an example of a fictitious
patient.
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